Abstract
San Antonio, Tex. This is an edited volume of 322 pages divided into 15 chapters. The editors have assembled a stellar group of academia and industry neuroscience contributors from the United States, Australia, Israel, and the United Kingdom. As the editors point out in the introduction, "one size does not fit all." The goal of the volume is to update the reader on the concept of personalized medicine and to support the idea that a better understanding of the genomic regulation and other biomarkers of mental disorders will lead to improved diagnoses and treatments. The first chapter, on the history of personalized medicine, reminds us that the concept is not a new one and provides examples going back to antiquity. Progress in the last 20 years, including public policy and legal aspects, is nicely summarized. The second chapter, by Alan Schatzberg, provides a concise review of mostly failed attempts to characterize psychiatric conditions with biological tests, such as tests for 3-methoxy-4-hydroxy-phenylethyleneglycol levels and hypothalamic pituitary adrenal axis activity or the dexamethasone/corticotropin-releasing hormone test. Section Two focuses on specific mental disorders. Unfortunately, only a few illnesses, such as schizophrenia, depression, and attention deficit hyperactivity disorder, are covered. Noted omissionsIf you're having problem loading pages
Try our single-page mode to load one page at a time


Preview Only. This article cannot be rented because we do not currently have permission from the publisher.
Preview Only
© 2012 DeepDyve, Inc. All rights reserved.
Terms of Service | Privacy Policy